2025 H1 -tulosraportti
173 päivää sitten
‧38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
2 000
Myynti
Määrä
10 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 846 | - | - | ||
| 1 318 | - | - | ||
| 665 | - | - | ||
| 335 | - | - |
Ylin
4,305VWAP
Alin
3,935VaihtoMäärä
17,6 4 271 482
VWAP
Ylin
4,305Alin
3,935VaihtoMäärä
17,6 4 271 482
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·12 min sittenThere wasn't much exciting to see on the top 50 list for the sell-off on Tuesday., actually nada. I think there was a lot of intraday trading.
·4 t sittenIt will be exciting to see the stock price development around February 27. This is Copilot’s perspective: 📈 How Index Inclusion Can Affect a Stock Price Thor Medical announced that it will be added to the MSCI World Micro Cap Index, effective at market close on February 27 1. While no outcome is guaranteed, index additions usually influence a stock in several well‑known ways: --- ✅ 1. Increased Demand From Index‑Tracking Funds Funds that track or benchmark against MSCI Micro Cap indexes may need to buy Thor Medical to stay aligned with the index. This mechanical buying can create short‑term upward pressure on the stock. • Example: MSCI’s index changes are implemented at the close on Feb 27, meaning trades from index replicators typically cluster around this date. 2 Possible effect: 📌 Short-term price bump leading up to or immediately after the inclusion date. --- ✅ 2. Higher Visibility and Credibility MSCI inclusion gives Thor Medical a place in a global peer universe of listed companies, increasing its international visibility (as they highlight themselves) 1. Why this could matter: • More global investors may notice the stock. • Analysts and funds sometimes screen companies based on MSCI membership. • Micro‑cap biotech firms often benefit disproportionately from visibility improvements. Possible effect: 📌 Medium-term increase in investor interest and liquidity. --- ✅ 3. Increased Liquidity Index inclusion typically boosts trading volume. Higher liquidity tends to: • Reduce bid/ask spreads • Make the stock more attractive to institutions • Support a more stable price over time Possible effect: 📌 More consistent trading and potentially smoother price movements over time. --- ⚠️ 4. Potential for Short-Term Volatility Index changes often bring: • Pre‑inclusion run‑ups, as traders anticipate index‑fund buying • Post‑inclusion pullbacks, once the mechanical buying is done This is common across MSCI index revisions. MSCI announces changes in advance and executes them on a set date (Feb 27) which traders may try to front‑run. 3 Possible effect: 📌 Temporary volatility around Feb 27. --- ⚠️ 5. Long-Term Impact Depends on Fundamentals While index inclusion is positive, its long-term effect depends on: • Company performance (in Thor’s case: biotech milestones, isotope production commercialization) • Investor sentiment toward the biotech/oncology space • Broader market conditions Thor is an emerging supplier in precision cancer therapies, which may attract long-term growth investors if fundamentals strengthen. 4
·2 t sittenAI; • Index funds have not bought yet. They operate according to fixed rules and make their purchases right before market close on February 27th. • This means there will be guaranteed buying pressure that day, regardless of whether "the news is old". "Keep an eye on the volume on February 27th at 16:20. That's when the large index orders usually hit the order book! "- ·9 t sittenIt's not just DNB that has come with price targets. A reminder of this : THOR MEDICAL: ARCTIC RAISES PRICE TARGET TO 5 (4), REITERATES BUY Close October 31, 2025 08:29 ∙ TDN Finans Oslo (Infront TDN Direkt): Arctic Securities raises the price target on Thor Medical to 5 kroner from 4 kroner and reiterates a buy recommendation on the share. This is evident from an analysis from the brokerage house on Friday. "Since we started coverage, there has been significant progress both within the radiopharmaceutical industry and at Thor Medical. The industry's momentum is still strong, with an increasing number of targeted radiation treatments in clinical phase, including a growing pipeline of Pb-212-based assets. Several projects, especially those involving Thor Medical's partners, are now moving beyond the preclinical phase", writes the brokerage house. Arctic now expects Thor Medical to generate revenue of 150 million kroner in 2027, up from 100 million kroner previously, and achieve ebitda break-even by the end of 2027.
·5 t sittenBut why does no one in management own shares, as far as I can see?·4 t sitten · MuokattuI seem to recall the CEO has an option for 3 million shares from earlier. May have changed. Well-motivated management is important. - ·9 t sittenBuy now or wait?
·8 t sittenI wasn't paying attention this morning but will try to increase a bit if it goes below 4 again.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H1 -tulosraportti
173 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 min sittenThere wasn't much exciting to see on the top 50 list for the sell-off on Tuesday., actually nada. I think there was a lot of intraday trading.
- ·4 t sittenIt will be exciting to see the stock price development around February 27. This is Copilot’s perspective: 📈 How Index Inclusion Can Affect a Stock Price Thor Medical announced that it will be added to the MSCI World Micro Cap Index, effective at market close on February 27 1. While no outcome is guaranteed, index additions usually influence a stock in several well‑known ways: --- ✅ 1. Increased Demand From Index‑Tracking Funds Funds that track or benchmark against MSCI Micro Cap indexes may need to buy Thor Medical to stay aligned with the index. This mechanical buying can create short‑term upward pressure on the stock. • Example: MSCI’s index changes are implemented at the close on Feb 27, meaning trades from index replicators typically cluster around this date. 2 Possible effect: 📌 Short-term price bump leading up to or immediately after the inclusion date. --- ✅ 2. Higher Visibility and Credibility MSCI inclusion gives Thor Medical a place in a global peer universe of listed companies, increasing its international visibility (as they highlight themselves) 1. Why this could matter: • More global investors may notice the stock. • Analysts and funds sometimes screen companies based on MSCI membership. • Micro‑cap biotech firms often benefit disproportionately from visibility improvements. Possible effect: 📌 Medium-term increase in investor interest and liquidity. --- ✅ 3. Increased Liquidity Index inclusion typically boosts trading volume. Higher liquidity tends to: • Reduce bid/ask spreads • Make the stock more attractive to institutions • Support a more stable price over time Possible effect: 📌 More consistent trading and potentially smoother price movements over time. --- ⚠️ 4. Potential for Short-Term Volatility Index changes often bring: • Pre‑inclusion run‑ups, as traders anticipate index‑fund buying • Post‑inclusion pullbacks, once the mechanical buying is done This is common across MSCI index revisions. MSCI announces changes in advance and executes them on a set date (Feb 27) which traders may try to front‑run. 3 Possible effect: 📌 Temporary volatility around Feb 27. --- ⚠️ 5. Long-Term Impact Depends on Fundamentals While index inclusion is positive, its long-term effect depends on: • Company performance (in Thor’s case: biotech milestones, isotope production commercialization) • Investor sentiment toward the biotech/oncology space • Broader market conditions Thor is an emerging supplier in precision cancer therapies, which may attract long-term growth investors if fundamentals strengthen. 4·2 t sittenAI; • Index funds have not bought yet. They operate according to fixed rules and make their purchases right before market close on February 27th. • This means there will be guaranteed buying pressure that day, regardless of whether "the news is old". "Keep an eye on the volume on February 27th at 16:20. That's when the large index orders usually hit the order book! "
- ·9 t sittenIt's not just DNB that has come with price targets. A reminder of this : THOR MEDICAL: ARCTIC RAISES PRICE TARGET TO 5 (4), REITERATES BUY Close October 31, 2025 08:29 ∙ TDN Finans Oslo (Infront TDN Direkt): Arctic Securities raises the price target on Thor Medical to 5 kroner from 4 kroner and reiterates a buy recommendation on the share. This is evident from an analysis from the brokerage house on Friday. "Since we started coverage, there has been significant progress both within the radiopharmaceutical industry and at Thor Medical. The industry's momentum is still strong, with an increasing number of targeted radiation treatments in clinical phase, including a growing pipeline of Pb-212-based assets. Several projects, especially those involving Thor Medical's partners, are now moving beyond the preclinical phase", writes the brokerage house. Arctic now expects Thor Medical to generate revenue of 150 million kroner in 2027, up from 100 million kroner previously, and achieve ebitda break-even by the end of 2027.·5 t sittenBut why does no one in management own shares, as far as I can see?·4 t sitten · MuokattuI seem to recall the CEO has an option for 3 million shares from earlier. May have changed. Well-motivated management is important.
- ·9 t sittenBuy now or wait?·8 t sittenI wasn't paying attention this morning but will try to increase a bit if it goes below 4 again.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
2 000
Myynti
Määrä
10 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 846 | - | - | ||
| 1 318 | - | - | ||
| 665 | - | - | ||
| 335 | - | - |
Ylin
4,305VWAP
Alin
3,935VaihtoMäärä
17,6 4 271 482
VWAP
Ylin
4,305Alin
3,935VaihtoMäärä
17,6 4 271 482
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
2025 H1 -tulosraportti
173 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 min sittenThere wasn't much exciting to see on the top 50 list for the sell-off on Tuesday., actually nada. I think there was a lot of intraday trading.
- ·4 t sittenIt will be exciting to see the stock price development around February 27. This is Copilot’s perspective: 📈 How Index Inclusion Can Affect a Stock Price Thor Medical announced that it will be added to the MSCI World Micro Cap Index, effective at market close on February 27 1. While no outcome is guaranteed, index additions usually influence a stock in several well‑known ways: --- ✅ 1. Increased Demand From Index‑Tracking Funds Funds that track or benchmark against MSCI Micro Cap indexes may need to buy Thor Medical to stay aligned with the index. This mechanical buying can create short‑term upward pressure on the stock. • Example: MSCI’s index changes are implemented at the close on Feb 27, meaning trades from index replicators typically cluster around this date. 2 Possible effect: 📌 Short-term price bump leading up to or immediately after the inclusion date. --- ✅ 2. Higher Visibility and Credibility MSCI inclusion gives Thor Medical a place in a global peer universe of listed companies, increasing its international visibility (as they highlight themselves) 1. Why this could matter: • More global investors may notice the stock. • Analysts and funds sometimes screen companies based on MSCI membership. • Micro‑cap biotech firms often benefit disproportionately from visibility improvements. Possible effect: 📌 Medium-term increase in investor interest and liquidity. --- ✅ 3. Increased Liquidity Index inclusion typically boosts trading volume. Higher liquidity tends to: • Reduce bid/ask spreads • Make the stock more attractive to institutions • Support a more stable price over time Possible effect: 📌 More consistent trading and potentially smoother price movements over time. --- ⚠️ 4. Potential for Short-Term Volatility Index changes often bring: • Pre‑inclusion run‑ups, as traders anticipate index‑fund buying • Post‑inclusion pullbacks, once the mechanical buying is done This is common across MSCI index revisions. MSCI announces changes in advance and executes them on a set date (Feb 27) which traders may try to front‑run. 3 Possible effect: 📌 Temporary volatility around Feb 27. --- ⚠️ 5. Long-Term Impact Depends on Fundamentals While index inclusion is positive, its long-term effect depends on: • Company performance (in Thor’s case: biotech milestones, isotope production commercialization) • Investor sentiment toward the biotech/oncology space • Broader market conditions Thor is an emerging supplier in precision cancer therapies, which may attract long-term growth investors if fundamentals strengthen. 4·2 t sittenAI; • Index funds have not bought yet. They operate according to fixed rules and make their purchases right before market close on February 27th. • This means there will be guaranteed buying pressure that day, regardless of whether "the news is old". "Keep an eye on the volume on February 27th at 16:20. That's when the large index orders usually hit the order book! "
- ·9 t sittenIt's not just DNB that has come with price targets. A reminder of this : THOR MEDICAL: ARCTIC RAISES PRICE TARGET TO 5 (4), REITERATES BUY Close October 31, 2025 08:29 ∙ TDN Finans Oslo (Infront TDN Direkt): Arctic Securities raises the price target on Thor Medical to 5 kroner from 4 kroner and reiterates a buy recommendation on the share. This is evident from an analysis from the brokerage house on Friday. "Since we started coverage, there has been significant progress both within the radiopharmaceutical industry and at Thor Medical. The industry's momentum is still strong, with an increasing number of targeted radiation treatments in clinical phase, including a growing pipeline of Pb-212-based assets. Several projects, especially those involving Thor Medical's partners, are now moving beyond the preclinical phase", writes the brokerage house. Arctic now expects Thor Medical to generate revenue of 150 million kroner in 2027, up from 100 million kroner previously, and achieve ebitda break-even by the end of 2027.·5 t sittenBut why does no one in management own shares, as far as I can see?·4 t sitten · MuokattuI seem to recall the CEO has an option for 3 million shares from earlier. May have changed. Well-motivated management is important.
- ·9 t sittenBuy now or wait?·8 t sittenI wasn't paying attention this morning but will try to increase a bit if it goes below 4 again.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
2 000
Myynti
Määrä
10 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 846 | - | - | ||
| 1 318 | - | - | ||
| 665 | - | - | ||
| 335 | - | - |
Ylin
4,305VWAP
Alin
3,935VaihtoMäärä
17,6 4 271 482
VWAP
Ylin
4,305Alin
3,935VaihtoMäärä
17,6 4 271 482
Välittäjätilasto
Dataa ei löytynyt